Cellectis preps for groundbreaking US trials for an off-the-shelf CAR-T therapy
Cellectis is ramping up the first-ever US trial launches for an off-the-shelf CAR-T therapy.
The Paris-based biotech $CLLS, which has a sizable R&D group in Manhattan, says the FDA has signed off on their IND for a Phase I study of UCART123 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
The plan now is to get started in the next few months, wrap up their early-stage work in early 2018 and then launch what they hope will be a registrational Phase II trial in mid-2018 — provided the FDA signs off, Dr. Loan Hoang-Sayag, Cellectis’ chief medical officer, tells Endpoints News via email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.